Azarga approved by EMEA

Article

Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.

Azarga (brinzolamide 10 mg/ml and timolol 5 mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.

A clinical trial has demonstrated that Azarga is as safe as, but more effective than, either of its constituent components, brinzolamide and timolol. A separate study showed that Azarga is as safe as Cosopt (timolol/dorzolamide fixed combination; Merck), but is better tolerated and more comfortable for patients.

Azarga will be available in Europe from early next year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
The International Space Station (ISS) pictured in orbit above Earth. Concept image for International Spectralis Symposium conference meeting in Heidelberg, Germany, and NASA. ©Paopano – stock.adobe.com

Long-duration spaceflight tests the limits of telemedicine

Sheryl Stevenson;Steven Laurie, PhD
July 3rd 2025
Article

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A person sits at their laptop with a cup of coffee visible in the foreground. Concept image for instant coffee, AMD, age related macular degeneration, ocular health and instant coffee investigation. Image credit: ©Ljustina – stock.adobe.com

Patients with high genetic risk of AMD should avoid instant coffee, investigators say

Lynda Charters
July 1st 2025
Article

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

A person's hands are visible as they search in a file cabinet. Concept image for new categorisation of intraocular lens. Image credit: ©Stephen Coburn – stock.adobe.com

How a newly defined category of IOLs can benefit patient outcomes

Joaquín Fernández Pérez, MD, PhD, MSc
June 30th 2025
Article

A new functional classification can help achieve precise vision goals

European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval

European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval

Martin David Harp
June 30th 2025
Article
Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Martin David Harp
June 26th 2025
Article

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

© 2025 MJH Life Sciences

All rights reserved.